Prescription Drug Overdose National Perspective

Slides:



Advertisements
Similar presentations
© March, In Their Own Right, 2002The Alan Guttmacher Institute (AGI) Why Worry About Men? Addressing mens sexual and reproductive health will help.
Advertisements

The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.
Chartpack National Scorecard on U.S. Health System Performance, 2011
National Scorecard, 2008: Chartpack This Chartpack presents data for all indicators scored in the National Scorecard on U.S. Health System Performance,
Older People with Dementia in Acute Care: K ey messages from the NAO report Paul Forte The Balance of Care Group
©2012 MFMER | slide-1 Family History Information Helps Inform Chronic Pain Treatment Elizabeth Pestka, MS, PMHCNS-BC, APNG Cynthia Townsend, PhD, LP Emily.
Cindy Powers Magrini, PharmD, BCPS
Opioid-Related Deaths and Mortality Rates by County, Wisconsin Residents Office of Health Informatics and AIDS/HIV and Hepatitis C Program Bureau.
Unintentional Drug Poisoning Deaths, Michigan Residents, Su Min Oh, PhD Michigan Department of Community Health Bureau of Substance Abuse and.
Preventing Deaths in Custody: Recommendations, Impacts and Change 13 th Biennial CCJA Congress Hyatt Regency Hotel Vancouver, BC October 5, –
Addressing Hypnotic medicines use in primary care
Asthma in Minnesota Slide Set Asthma Program Minnesota Department of Health January 2013.
Learning by Comparing: Experiences of Adults in Eleven Countries Findings from the Commonwealth Fund 2013 International Health Policy Survey and Health.
PROCESS vs. WA State SCS Study A Comparison of Study Design, Patient Population, and Outcomes August 29,2007.
Project Lazarus A community-wide response to managing pain.
Is Persistent (Chronic) Pain a Preventable Disease Ruben Halperin, MD MPH May 31, 2014.
Click the arrows to advance forward and backward. Click the Next link below to advance to the assessment. The A B C & D’s of Suicide Assessment and Clinical.
Diverse Children: Race, Ethnicity, and Immigration in America’s New Non-Majority Generation by Donald J. Hernandez, Ph.D. Hunter College, City University.
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
Innovative Approach of Managing High Risk Chronic Opioid Users in a Residency Practice Erin Inglis, MD a, Jessie Burch, PharmD b, Nida Awadallah, MD c,,
The purpose is not to imply everyone on controlled substances will become addicted!!! Everyone on controlled substances is, however, at increased risk.
Update on the 2015 Agency Medical Directors’ Group’s (AMDG’s) Interagency Guideline on Prescribing Opioids for Pain.
Sublingual Buprenorphine and Pain
TM Centers for Disease Control and Prevention National Center for Injury Prevention and Control Centers for Disease Control and Prevention National Center.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Medical Director Jackson County Health and Human Services
MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Characteristics of Patients Using Extreme Opioid Dosages in the Treatment of Chronic Low Back Pain In this sample of 204 participants, 70% were female,
Introduction to Pain/Opioid Management
Opioid Use: What are the technological, clinical, ethical, and regulatory issues? Michael Von Korff Group Health Research Institute.
Opioid Use in Work-related Injuries Pacific Northwest Chapter - Association of Occupational Health Professionals (AOHP) January 4, 2011 Jaymie Mai, PharmD.
1 Alcohol and Substance Abuse Council of Jefferson County, Inc. 167 Polk Street, Suite 320 Watertown, New York Voice: ; Fax: ;
Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Opioid Use in Workers’ Compensation Suzanne Novak, MD, PhD November 2008.
Origin and Process of Utah Guidelines Anna Fondario, MPH Utah Department of Health Violence and Injury Prevention Program.
Opioid Compliance, Documentation, and Monitoring October 9, 2015.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Sedative-hypnotic guideline, BHS
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
SARAH M. BAGLEY, MD ASSISTANT PROFESSOR OF MEDICINE AND PEDIATRICS BOSTON UNIVERSITY SCHOOL OF MEDICINE AMERSA ANNUAL CONFERENCE NOVEMBER 5, 2015 Overdose.
Prevention, Identification and Treatment of Opioid Use Disorders: A Personal Perspective Leah Bauer, MD Medical Director, Addiction Resource Center, Mid.
Pain Management: Narcotics, Implantable Therapies Maher Fattouh MD Adjunct Assistant Clinical Professor University Wisconsin Medical Director, Advanced.
CDC Guideline for Prescribing Opioids for Chronic Pain Presenter’s Name Presenter’s Title Title of Event Date of Event Centers for Disease Control and.
Implementing a Urine Drug Screening Protocol to Teach Appropriate Opioid Prescribing in a Residency Practice STFM Annual Conference May 2, 2016 Nata Young,
Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
A System to Manage Long Term Opioid Prescribing in the Primary Care Setting Joy Nassar, MD University Medicine Foundation November 16, 2015.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
Responding to the Opioid Addiction Epidemic Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for.
The AMA: Reducing Opioid Abuse in America Patrice A. Harris, MD, MA Board Chair American Medical Association September 2016.
CDC Guideline for Prescribing Opioids for Chronic Pain- United States-2016 Gisele J. Girault, M.D. First Choice Healthcare Columbia, SC.
Current Concepts in Pain Management
Cover slide.
Opioid Prescribing CAPT Thomas Weiser, MD, MPH Medical Epidemiologist
Opioids Aware A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.
6-Building Block Workshop
Medication-Assisted Therapy at Coleman Profession Services
Caldwell County Narcotic Initiative
Introduction to Clinical Pharmacy
STOP! Safe Treatment of Pain
Opioids – A Pharmaceutical Perspective on Prescription Drugs
Opioid Prescribing & Monitoring
Barbara Allison-Bryan, MD
Opioids in Butte County
Impact of Policy and Regulatory Responses to the Opioid Epidemic on the Care of People with Serious Illness Hemi Tewarson, Director, Health Division National.
Essentials of Good Pain Care: A Team-Based Approach
Tapering and Discontinuing Chronic Opioid Therapy
Pain Management JEFFREY TAN HO, D.O.
Presentation transcript:

Prescription Drug Overdose National Perspective Len Paulozzi, MD, MPH Division of Unintentional Injury Prevention National Center for Injury Prevention and Control Centers for Disease Control and Prevention Arizona Opioid Prescribing Summit, March 15, 2014 National Center for Injury Prevention and Control Division of Unintentional Injury Prevention

Outline of presentation State comparisons States with opioid guidelines Common elements of guidelines Guideline adherence Impacts of guidelines reported by states

Motor vehicle traffic, poisoning, and drug poisoning (overdose) death rates, US, 1980-2010 NCHS Data Brief, December, 2011, Updated with 2009 and 2010 mortality data

Drug overdose deaths by major drug type, US, 1999-2010 16,651 CDC/NCHS National Vital Statistics System, CDC Wonder.

Death Rates for Drug Overdose by State, 2010 13.1 12.9 10.4 3.4 12.9 7.3 11.8 10.9 6.3 7.8 15.0 13.9 8.6 15.3 NH 11.8 20.7 6.7 16.1 VT 9.7 16.9 10.0 14.4 MA 11.0 10.6 12.7 28.9 RI 15.5 9.6 17.0 6.8 23.6 CT 10.1 NJ 9.8 17.5 11.4 16.9 DE 16.6 19.4 MD 11.0 23.8 12.5 14.6 DC 12.9 11.4 11.8 10.7 9.6 13.2 Arizona ranked sixth nationally in 2010. Data: WONDER multiple causes mortality files, age-adjusted death rates for 2010. Deaths whose underlying cause was coded to unintentional (X40-44), intentional (X60-64, X85), or undetermined intent (Y10-14) drug poisoning. Source: Centers for Disease Control and Prevention , National Center for Health Statistics. Multiple Cause of Death 1999-2010 on CDC WONDER Online Database, released 2012. Data are from the Multiple Cause of Death Files, 1999-2010, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at http://wonder.cdc.gov/mcd-icd10.html 16.4 11.6 10.9 3.4 - 10.9* 10.9* - 13.9 14.0 - 28.9 Age-adjusted rate per 100,000 population Footnote: *10.9 is in two ranges due to rounding. HI is 10.88 while WI is 10.94

Opioid analgesic prescribing rates, United States, 2011 Arizona had the 5th highest rate among states in 2011. Behind, NV, FL, TN, and DE.

Recent state opioid analgesic prescribing guidelines for chronic pain Year(s) Washington State Agency Medical Directors Group Interagency Guideline on Opioid Dosing for Chronic Noncancer Pain 2007, 2010 Utah Clinical Guidelines on Prescribing Opioids for Treatment of Pain 2009 New York City Opioid Prescribing Guidelines 2011 New Mexico Clinical Guidelines on Prescribing Opioids for Treatment of Pain Ohio Guidelines for Prescribing Opioids for the Treatment of Chronic, Non-Terminal Pain 2013 Indiana Healthcare Providers Guide to the Safe, Effective Management of Chronic Non‐Terminal Pain Opioid Prescribing Guidelines for Oklahoma Health Care Providers in the Office-Based Setting 2014 In general, if the guidelines do not specify “chronic” pain in their title, they will have material related to acute pain.

Features of opioid guidelines by state: Pre-treatment Recommendation* UT WA NYC NM OH IN OK Assess onset, location, quality, duration, and intensity of pain Y Assess current level of function and change over time Review previous treatments for pain, including prior medication use, and their results Screen for personal or family history of mental health or substance use disorders Determine pregnancy status of patient   Check Prescript Drug Monitor Program (PDMP)  * Conduct a physical exam Conduct a urine drug test (UDT) Indication: Opioids are for moderate to severe pain that has failed other indicated therapies LANGUAGE VARIES, FROM DIRECTIONS TO DO SOMETHING TO PHRASES SUCH AS “CONSIDER….” WA did not have a PMP in 2010 when the latest edition of their guidelines was published. Pregnancy screening is widely recommended in guidelines of professional societies, eg, AAPM/APS *Recommendation listed here might differ from the wording in the guideline.

Features of opioid guidelines by state: Initial opioid treatment Recommendation* UT WA NYC NM OH IN OK LA/ER opioids should not usually be used as first-line agents Y Methadone is generally not considered a first-line opioid for chronic pain   The lowest effective dose should be given Initial course of treatment should be considered a trial and short-term (lasting from several weeks to several months) Do not combine opioids with sedative-hypnotics such as benzodiazepines or barbiturates unless there is a specific medical and/or psychiatric indication Y  Informed consent and a signed treatment agreement should be executed Utah talks about determining whether patients are taking sedatives but does not explicitly state that they should not be combined with opioids. WA in contrast says “do not combine…unless there is a specific medical indication.” *Recommendation listed here might differ from the wording in the guideline.

Features of opioid guidelines by state: At each follow-up visit Recommendation* UT WA NYC NM OH IN OK Assess pain intensity, level of function, adverse events, aberrant drug-related behavior Y Y80 Reassess treatment progress and treatment plan and consider other pain management approaches if patient receiving ≥ a specific dose in Morphine Mg Equivalent (MME)/day 120-200 120 100 80 30 Do not combine opioids with sedative-hypnotics such as benzodiazepines or barbiturates unless there is a specific medical and/or psychiatric indication   Y  Check PDMP  Y *  Conduct periodic random UDT on all patients receiving chronic opioid therapy. (yearly for low-risk and up to every 3 months for high-risk). Screen if patient demonstrates aberrant behavior Ohio calls 80 MED a trigger point. Recommendations labeled “Y80” above apply only to patients at this dosage for 3 months or more. WA did not have an operative PDMP in 2010 when the guidelines were updated. *Recommendation listed here might differ from the wording in the guideline.

Features of opioid guidelines by state: Opioid discontinuation Recommendation* UT WA NYC NM OH IN OK Primary reasons for discontinuation include: no progress toward meeting therapeutic goals; serious or repeated aberrant drug related behaviors or drug diversion; intolerable side effects Y Specific tapering strategies suggested, e.g., a 10% reduction in dose per week up to 25-50% reduction every few days If patient is suspected of meeting criteria for opioid dependence, explain treatment options and refer patient to an addiction specialist, buprenorphine providers, or methadone maintenance treatment program.   *Recommendation listed here might differ from the wording in the guideline.

General findings in evaluating opioid prescribing guidelines Wide variation (38%-66%) fraction of providers unaware of guidelines Overall low level of adherence Some components more likely to be adopted than others

Challenges to guideline adherence Lack of familiarity Conflicting recommendations among guidelines Lack of empirical evidence to support recommendations Work flow obstacles, e.g., time required to check PDMPs Resource obstacles, e.g., lack of insurance coverage for options to opioids/urine tests, or lack of specialists for referrals

Changes in prescriber behavior after Washington State 2007 opioid prescribing guidelines Survey in 2011 of prescribers asked: “Has your opioid prescribing for chronic, noncancer pain changed in the past 3 years?” Response rates <11% Responses: Now prescribes opioids to More CNCP patients, 10.5% Fewer CNCP patients, 44.4% Stopped prescribing, 3.3% Now prescribes Higher doses more often, 5.7% Higher doses less often, 46.6% Source: Franklin et al. Changes in opioid prescribing for chronic pain in Washington State. JABFM 2013; 26(4):394-400

Changes in opioid prescribing to workers compensation claimants after Washington State 2007 opioid prescribing guidelines Trends 1996-2010 in workers compensation system Findings Number of CSII and CSIII opioid rx declined Mean MED declined 27% in 2002-2010 Proportion of claimants on opioids declined 37% Proportion of claimants on 120+ MED declined 35% Opioid-related deaths rose through 2009 and dropped sharply in 2010 Source: Franklin et al. Bending the prescription opioid dosing and mortality curves: impact of the Washington State Opioid Dosing Guideline. Am J Ind Med 2012; 55:325-331

Unintentional Prescription Opioid Overdose Deaths Washington 1995-2012 There was a coding change that became effective in 2009, which included tramadol as an opioid code. Deaths with tramadol as the only opiate were excluded prior to 2009. In 2009, there were 9 such deaths. It is likely that the decline from 2008 to 2009 would be slightly larger if tramadol only deaths had been included previously. * Tramadol only deaths included in 2009, but not in prior years. Source: Washington State Department of Health, Death Certificates 16

Adherence to Utah prescribing guidelines Utah guidelines published in 2009 Followed by academic detailing campaign Survey of 47 prescribers (55% response rate) of a university-based community clinic system in 2011 Source: Porucznik, et al. Opioid prescribing knowledge and practices: provider survey following promulgation of guidelines—Utah, 2011. J Opioid Manage 2013;9:217-223

Results of Utah prescribing guidelines survey Among the 47 respondents: 77% prescribed opioids for chronic noncancer pain (CNCP) 39% were familiar with the guidelines 37% read them but didn’t remember them 72% used random urine toxicology tests for CNCP patients 41% used patient contracts always Source: Porucznik, et al. Opioid prescribing knowledge and practices: provider survey following promulgation of guidelines—Utah, 2011. J Opioid Manage 2013;9:217-223

Number of occurrent* prescription-opioid deaths by year, Utah, 2000-2011 *Occurrent deaths include all individuals who died in Utah, whether or not they were a resident of Utah. Source: Utah Department of Health. Prescription opioid deaths in Utah, 2011. At: http://useonlyasdirected.org/docs/RxOpioidDeaths.pdf

Conclusions State guidelines for opioid prescribing for chronic pain proliferating In general, guidelines components are similar, but language, obligation, and circumstances for action vary Challenges to adherence as in any educational intervention Clear evidence of effectiveness difficult to obtain --- overall or for specific components of guidelines

Thank you Len Paulozzi, MD, MPH lpaulozzi@cdc.gov The findings and conclusions in this report are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry. The presenter has no conflicts of interest.